skip to main content

Pulmonary Haemorrhage AAV — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardVasculitisPulmonary Haemorrhage AAVSCE Rheumatology

An adult with relapsing EGPA has recurrent asthma, nasal polyposis and eosinophilic inflammation despite glucocorticoid-sparing therapy. There is no cardiac, renal, gastrointestinal or neurological threat. Which add-on regimen is licensed?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Mepolizumab 300 mg subcutaneously every 4 weeks

Explanation lettering: E = shown as D · D = shown as E

B is correct. The UK mepolizumab SmPC specifies 300 mg subcutaneously every 4 weeks for adult relapsing-remitting or refractory EGPA. The 100 mg dose is used for severe eosinophilic asthma, not the licensed adult EGPA schedule. Mepolizumab has not been studied as the solution to life-threatening EGPA, which would require organ-threatening induction.

Reference: Mepolizumab UK SmPC. https://www.medicines.org.uk/emc/product/1938/smpc